Abstract
Immune checkpoint inhibitors have revolutionized the treatment of patients with advanced and metastatic melanoma and led to prolonged overall survival. However, long-term treatment responses are still limited to few patients, where tumor-specific effector T cells at the tumor sites are considered predictors for treatment success. This raises the question of new treatment strategies. We were recently able to show in preclinical models, that targeted activation of melanoma-associated mast cells (MC) with lipopolysaccharide (LPS) induces an effective anti-melanoma immune response in a TLR4-dependent manner.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
